GlassScriptPhysician profile
Frederick W Reimherr
NPI 1740259795
$18,178.72
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $11.60 · 2021: $2,300 · 2022: $304.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $9,263.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $4,571.04 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $2,025.00 | 2021 | |
| Janssen Research & Development, LLC | $1,375.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $141.53 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.67 | 2019-2021 | |
| Abbvie INC. | $117.95 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $97.51 | 2019-2022 | |
| Biogen, INC. | $94.52 | 2022 | |
| Neurocrine Biosciences, INC. | $94.35 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $77.05 | 2019 | |
| Janssen Scientific Affairs, LLC | $69.80 | 2019 | |
| Ironshore Pharmaceuticals INC. | $67.52 | 2019-2021 | |
| Neuronetics, INC. | $33.56 | 2019 | |
| Lundbeck LLC | $16.28 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Research and ownership
$4,253.24 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Reimherr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.